Markets applaud strong finish to 2025 and better-than-expected 2026 outlook
12/02/26 -"Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed consensus expectations, boosting investor ..."
Pages
50
Language
English
Published on
12/02/26
You may also be interested by these reports :
12/02/26
Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed ...
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...